MA27453A1 - Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations - Google Patents

Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations

Info

Publication number
MA27453A1
MA27453A1 MA28215A MA28215A MA27453A1 MA 27453 A1 MA27453 A1 MA 27453A1 MA 28215 A MA28215 A MA 28215A MA 28215 A MA28215 A MA 28215A MA 27453 A1 MA27453 A1 MA 27453A1
Authority
MA
Morocco
Prior art keywords
nachr
compounds
benzoisothiazoles
indazoles
benzothiazoles
Prior art date
Application number
MA28215A
Other languages
English (en)
Inventor
Ashok Tehim
Brian Herbert
Truc Minh Nguyen
Wenge Xie
Carla Maria Gauss
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32045238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27453(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of MA27453A1 publication Critical patent/MA27453A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)

Abstract

La présente invention concerne généralement le domaine des ligands pour les récepteurs de l'acétylcholine nicotiniques (nAChR), l'activation des nAChR et le traitement des états pathologiques associés aux récepteurs de l'acétylcholine nicotiniques défectueux ou défaillants, spécialement du cerveau. En outre, cette invention concerne de nouveaux composés (indazole et benzothiazole), qui agissent en tant que ligands pour le sous-type nAChR (alpha)-7, des procédés de préparation de tels composés, des compositions contenant de tels composés, et des procédés d'utilisation de ceux-ci.
MA28215A 2002-09-25 2005-04-12 Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations MA27453A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41315102P 2002-09-25 2002-09-25
US44846903P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
MA27453A1 true MA27453A1 (fr) 2005-07-01

Family

ID=32045238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28215A MA27453A1 (fr) 2002-09-25 2005-04-12 Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations

Country Status (25)

Country Link
US (6) US7429664B2 (fr)
EP (2) EP1543000B1 (fr)
JP (2) JP4890762B2 (fr)
KR (1) KR101129933B1 (fr)
CN (1) CN100484937C (fr)
AU (1) AU2003276919B2 (fr)
BG (1) BG109117A (fr)
BR (1) BR0314485A (fr)
CA (1) CA2499128C (fr)
CZ (1) CZ2005252A3 (fr)
EC (1) ECSP055699A (fr)
EE (1) EE05516B1 (fr)
ES (1) ES2405594T3 (fr)
HR (1) HRP20050266A2 (fr)
HU (1) HUP0500610A3 (fr)
MA (1) MA27453A1 (fr)
MX (1) MXPA05003317A (fr)
NO (1) NO332535B1 (fr)
NZ (1) NZ539049A (fr)
PL (1) PL210065B1 (fr)
RS (1) RS53147B (fr)
RU (1) RU2391341C2 (fr)
SK (1) SK288115B6 (fr)
WO (1) WO2004029050A1 (fr)
ZA (1) ZA200502465B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CA2499128C (fr) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations
AU2012202336B2 (en) * 2004-03-25 2015-01-22 Memory Pharmaceuticals Corporation Indazoles, Benzothiazoles, Benzoisothiazoles, Benzisoxazoles, and Preparation and Uses Thereof
WO2005092890A2 (fr) * 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
DE602005024677D1 (de) * 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008525464A (ja) * 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
AU2006214184B2 (en) * 2005-02-17 2012-02-02 Albany Molecular Research, Inc. Benzoxazole carboxamides for treating CINV and IBS-D
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
CN101312968A (zh) * 2005-09-23 2008-11-26 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑、吡唑并吡啶、异噻唑并吡啶及其制备和用途
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
WO2007056582A1 (fr) * 2005-11-09 2007-05-18 Memory Pharmaceuticals Corporation 1-h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles et chromones, et leur preparation et utilisations
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CN101528225B (zh) * 2006-08-07 2013-07-17 阿尔巴尼分子研究公司 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺
US20080153810A1 (en) * 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
SG173409A1 (en) * 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
US8106215B2 (en) 2007-07-03 2012-01-31 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2178870B1 (fr) * 2007-08-17 2018-09-19 LG Chem, Ltd. Composés d'indole et d'indazole en tant qu'inhibiteurs de nécrose cellulaire
DK2217597T3 (da) * 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
KR101186704B1 (ko) 2007-10-04 2012-09-27 에프. 호프만-라 로슈 아게 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도
EP2271344A4 (fr) * 2008-03-31 2011-04-27 Univ South Florida Méthodes de traitement d'une ataxie et d'un déséquilibre non-ataxique induits par une maladie
JP2011520964A (ja) * 2008-05-23 2011-07-21 ユニバーシティ・オブ・サウス・フロリダ ニコチン性アセチルコリン受容体活性を有する化合物を用いる末梢感覚神経喪失の治療方法
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2012521429A (ja) * 2009-03-23 2012-09-13 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
EP2311823A1 (fr) 2009-10-15 2011-04-20 AC Immune S.A. Composés de 2,6-diaminopyridine appropriés pour le traitement de maladies liées à des protéines amyloïdes ou pour le traitement de maladies oculaires
US20110172428A1 (en) 2010-01-12 2011-07-14 Shan-Ming Kuang Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt
JP2013526542A (ja) 2010-05-12 2013-06-24 アッヴィ・インコーポレイテッド キナーゼのインダゾール阻害薬
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
US8242276B2 (en) 2010-06-30 2012-08-14 Hoffmann-La Roche Inc. Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt
CA2808797A1 (fr) 2010-07-26 2012-02-02 Envivo Pharmaceuticals, Inc. Traitement de troubles cognitifs par certains agonistes du recepteur alpha-7 de l'acide nicotinique en combinaison a des inhibiteurs d'acetylcholinesterase
EP2632268A4 (fr) * 2010-10-29 2014-09-10 Merck Sharp & Dohme Nouveaux composés qui sont des inhibiteurs de erk
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
CA2824970C (fr) 2011-02-11 2016-05-03 Batmark Limited Element inhalateur
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
IN2014CN03647A (fr) 2011-10-20 2015-10-09 Novartis Ag
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
BR112015013771B1 (pt) 2012-12-11 2022-10-04 Novartis Ag Composição que compreende um ativador do receptor alfa 7, nicotínico de acetilcolina (nachr) como biomarcador preditivo de resposta ao tratamento de ativador do dito receptor
JP6137336B2 (ja) * 2013-01-15 2017-05-31 ノバルティス アーゲー ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用
MX379289B (es) 2013-01-15 2025-03-10 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
US20150313884A1 (en) * 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
EP2945633B1 (fr) 2013-01-15 2021-06-30 Novartis AG Utilisation d'agonistes du recepteur nicotinique de l' acetylcholine alpha 7
BR112016021626A2 (pt) 2014-03-20 2018-05-15 Samumed, Llc indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
JP7055017B2 (ja) 2014-09-29 2022-04-15 武田薬品工業株式会社 結晶形の１－（１－メチル－１ｈ－ピラゾール－４－イル）－ｎ－（（１ｒ，５ｓ，７ｓ）－９－メチル－３－オキサ－９－アザビシクロ［３．３．１］ノナン－７－イル）－１ｈ－インドール－３－カルボキサミド
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
JP6815417B2 (ja) * 2016-12-26 2021-01-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規化合物及びその薬理的に許容される塩
CN108689938B (zh) * 2017-04-10 2021-07-30 西华大学 多取代的吲唑类化合物及其作为ido抑制剂的用途
US11926596B2 (en) 2017-07-21 2024-03-12 Kadmon Corporation, Llc Inhibitors of Rho associated coiled-coil containing protein kinase
CN111050766A (zh) * 2017-07-21 2020-04-21 卡德门企业有限公司 Rho相关含卷曲螺旋蛋白激酶的抑制剂
WO2019057946A1 (fr) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Composés aromatiques multi-cycliques utilisés en tant qu'inhibiteurs du facteur d
JP7369132B2 (ja) 2018-02-23 2023-10-25 サミュメッド リミテッド ライアビリティ カンパニー ５－ヘテロアリール置換イミダゾール－３－カルボキサミドならびにその調製および使用の方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
FR2531083B1 (fr) 1982-06-29 1986-11-28 Sandoz Sa Nouveaux derives de la piperidine, leur preparation et leur utilisation comme medicaments
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2548666A1 (fr) 1983-07-08 1985-01-11 Delalande Sa Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique
DE3429830A1 (de) 1983-08-26 1985-03-07 Sandoz-Patent-GmbH, 7850 Lörrach Automatische carbonsaeure- und sulfonsaeureester oder -amide
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3687080T2 (de) 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
US4937247A (en) 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8623142D0 (en) 1986-09-26 1986-10-29 Beecham Group Plc Compounds
GB8518658D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
US5204356A (en) 1985-07-24 1993-04-20 Glaxo Group Limited Treatment of anxiety
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
IN166416B (fr) 1985-09-18 1990-05-05 Pfizer
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
US5098909A (en) 1987-11-14 1992-03-24 Beecham Group, P.L.C. 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
EP0350130A3 (fr) 1988-07-07 1991-07-10 Duphar International Research B.V 1H-indazoles 1,7-annelés substitués
US4895943A (en) 1988-10-25 1990-01-23 Pfizer Inc. Preparation of 1,4-diazabicyclo(3.2.2)nonane
US5223625A (en) 1988-12-22 1993-06-29 Duphar International Research B.V. Annelated indolo [3,2,-C]lactams
EP0377238A1 (fr) 1988-12-22 1990-07-11 Duphar International Research B.V Indolo(3,2-c)-lactames annelés
WO1990014347A1 (fr) 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Derives d'indole et medicament
US5446050A (en) 1989-11-17 1995-08-29 Pfizer Inc. Azabicyclo amides and esters as 5-HT3 receptor antagonists
GB8928837D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Pharmaceuticals
US5098889A (en) 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
US5192770A (en) 1990-12-07 1993-03-09 Syntex (U.S.A.) Inc. Serotonergic alpha-oxoacetamides
HU211081B (en) 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
AU1161292A (en) 1991-01-09 1992-08-17 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
AU652434B2 (en) 1991-03-01 1994-08-25 University Of Florida Research Foundation, Inc. Use of nicotinic analogs for treatment of degenerative diseases of the nervous system
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
EP0659078B1 (fr) 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Derives d'anabaseine utilises dans le traitement de troubles degeneratifs du systeme nerveux
US5679673A (en) 1992-09-24 1997-10-21 The United States Of America, Represented By The Department Of Health And Human Services Aralkyl bridged diazabicycloalkane derivatives for CNS disorders
IT1256623B (it) 1992-12-04 1995-12-12 Federico Arcamone Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
GB9226573D0 (en) 1992-12-21 1993-02-17 Ici Plc Heterocyclic compounds
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9406857D0 (en) 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
ATE208760T1 (de) 1995-12-21 2001-11-15 Syngenta Participations Ag 3-amino-2-mercaptobenzoesäure-derivate und verfahren zu ihrer herstellung
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5714946A (en) 1996-04-26 1998-02-03 Caterpillar Inc. Apparatus for communicating with a machine when the machine ignition is turned off
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
KR100247563B1 (ko) 1997-07-16 2000-04-01 박영구 키랄3,4-에폭시부티르산및이의염의제조방법
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
FR2791678B1 (fr) 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6313110B1 (en) 1999-06-02 2001-11-06 Dupont Pharmaceuticals Company Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor
DE19928846A1 (de) 1999-06-24 2001-03-08 Bosch Gmbh Robert Common-Rail-Injektor
HUP0203514A3 (en) 1999-09-28 2004-01-28 Eisai Co Ltd Quinuclidine compounds and drugs containing them and process for preparation the same
SE9903760D0 (sv) * 1999-10-18 1999-10-18 Astra Ab New compounds
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
SE9903997D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
US6747638B2 (en) * 2000-01-31 2004-06-08 Semiconductor Energy Laboratory Co., Ltd. Adhesion type area sensor and display device having adhesion type area sensor
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
EP1289996B1 (fr) 2000-05-25 2005-04-06 Targacept, Inc. Heteroaryldiazabicycloalkanes comme ligands du recepteur cholinergique nicotinique
FR2809732B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (fr) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
WO2002015662A2 (fr) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
AU2002211176A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
DE60216830T2 (de) 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
ATE289310T1 (de) 2001-06-01 2005-03-15 Neurosearch As Heteroaryl-diazabicycloalkanderivaten als cns- modulatoren
EP1403255A4 (fr) 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
CA2460075A1 (fr) 2001-09-12 2003-03-20 Donn Gregory Wishka 7-aza`2.2.1!bicycloheptanes substitues pour traitement de maladies
CZ2004408A3 (cs) 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005511574A (ja) 2001-10-26 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー Ｎａｃｈｒアゴニストとしてのｎ−アザビシクロ−置換ヘテロ二環式カルボキサミド
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) * 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10305922A1 (de) 2002-06-10 2004-03-04 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2476624A1 (fr) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Composes azabicycliques servant a traiter des maladies
MXPA04007083A (es) 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ES2197001B1 (es) 2002-03-26 2004-11-16 Laboratorios Vita, S.A. Procedimiento de obtencion de un compuesto farmaceuticamente activo.
AU2003222738B2 (en) 2002-05-07 2009-09-17 Neurosearch A/S Novel azacyclic ethynyl derivatives
AU2003227522A1 (en) 2002-05-30 2003-12-19 Neurosearch A/S 3-substituted quinuclidines and their use
ES2276072T3 (es) 2002-06-10 2007-06-16 Bayer Healthcare Ag Amidas de acidos 2-heteroarilcarboxilicos.
WO2004014922A1 (fr) 2002-08-10 2004-02-19 Astex Technology Limited Composes 3-(carbonyl) 1h-indazole utilises en tant qu'inhibiteurs de kinases cycline-dependantes (cdk)
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
CA2499128C (fr) 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
US7456171B2 (en) 2002-10-08 2008-11-25 Sanofi-Aventis 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
MXPA05007689A (es) 2003-01-22 2005-09-30 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
DE10334724A1 (de) 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Also Published As

Publication number Publication date
NZ539049A (en) 2007-02-23
US7943773B2 (en) 2011-05-17
EP1543000B1 (fr) 2013-03-06
ZA200502465B (en) 2006-01-25
HUP0500610A2 (hu) 2005-11-28
RU2391341C2 (ru) 2010-06-10
JP4890762B2 (ja) 2012-03-07
ECSP055699A (es) 2005-05-30
HUP0500610A3 (en) 2013-12-30
ES2405594T3 (es) 2013-05-31
RS53147B (sr) 2014-06-30
KR101129933B1 (ko) 2012-03-23
CA2499128C (fr) 2012-07-31
WO2004029050A1 (fr) 2004-04-08
JP2011140509A (ja) 2011-07-21
SK288115B6 (sk) 2013-09-03
PL210065B1 (pl) 2011-11-30
RS20050248A (sr) 2007-08-03
MXPA05003317A (es) 2005-07-05
CA2499128A1 (fr) 2004-04-08
NO20051985L (no) 2005-06-09
EE05516B1 (et) 2012-02-15
AU2003276919A1 (en) 2004-04-19
BR0314485A (pt) 2005-07-26
US20080176890A1 (en) 2008-07-24
PL375764A1 (en) 2005-12-12
US20090209579A1 (en) 2009-08-20
US20120101094A1 (en) 2012-04-26
US8134003B2 (en) 2012-03-13
RU2005112712A (ru) 2006-02-27
EP1543000A1 (fr) 2005-06-22
CN100484937C (zh) 2009-05-06
EP2305675A1 (fr) 2011-04-06
US20110212957A1 (en) 2011-09-01
CN1684962A (zh) 2005-10-19
US20080154037A1 (en) 2008-06-26
CZ2005252A3 (cs) 2005-11-16
EE200500011A (et) 2005-06-15
US20040132790A1 (en) 2004-07-08
NO332535B1 (no) 2012-10-15
JP2006503851A (ja) 2006-02-02
HK1083831A1 (zh) 2006-07-14
SK50322005A3 (sk) 2005-10-06
BG109117A (bg) 2005-12-30
US7429664B2 (en) 2008-09-30
US8252811B2 (en) 2012-08-28
KR20050069999A (ko) 2005-07-05
AU2003276919B2 (en) 2013-05-16
HRP20050266A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
MA28228A1 (fr) Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation
MA28972B1 (fr) Indazoles, benzothiazoles , benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
DE602005024677D1 (de) Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
SG165417A1 (en) Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
NO20051985L (no) Indazoler, benzotiazoler og benzoisotiazoler, samt fremstilling og anvendelser derav.
TNSN07411A1 (fr) Derives de 2-amido-6-amino-8-oxopurine servant de modulateurs des recepteurs du type toll pour le traitement du cancer et d'infections virales, telles que l'hepatite c.
IL179033A0 (en) 1h-indazoles, benzothiazoles, 1,2-benzoisozazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA30405B1 (fr) Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30021B1 (fr) Ligands presentant une specificite de liaison avec l'egfr et/ou le vegf et leurs procedes d'utilisation
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
TNSN07071A1 (fr) Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases